Active Ingredient: Voriconazole
Treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei).
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
16 - 18 mg per kg of body weight
From 8 To 9 mg per kg of body weight 2 time(s) per day every day
18 mg per kg of body weight
16 mg per kg of body weight
Voriconazole should be dosed as children as these young adolescents may metabolize voriconazole more similarly to children than to adults.
The recommended dosing regimen is as follows:
| Intravenous | Oral | |
|---|---|---|
| Loading Dose Regimen (first 24 hours) | 9 mg/kg every 12 hours | Not recommended |
| Maintenance Dose (after first 24 hours) | 8 mg/kg twice daily | 9 mg/kg twice daily (a maximum dose of 350 mg twice daily |
Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to <12 years and 26 immunocompromised adolescents aged 12 to <17 years.
It is recommended to initiate the therapy with intravenous regimen, and oral regimen should be considered only after there is a significant clinical improvement. It should be noted that an 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.
If patient response to treatment is inadequate, the intravenous dose may be increased by 1 mg/kg steps. If patient is unable to tolerate treatment, reduce the intravenous dose by 1 mg/kg steps.
It is recommended that voriconazole is administered at a maximum rate of 3 mg/kg per hour over 1 to 3 hours.
Oral
18 - 18 mg per kg of body weight
From 9 To 9 mg per kg of body weight 2 time(s) per day every day
Voriconazole should be dosed as children as these young adolescents may metabolize voriconazole more similarly to children than to adults.
The recommended dosing regimen is as follows:
| Intravenous | Oral | |
|---|---|---|
| Loading Dose Regimen (first 24 hours) | 9 mg/kg every 12 hours | Not recommended |
| Maintenance Dose (after first 24 hours) | 8 mg/kg twice daily | 9 mg/kg twice daily (a maximum dose of 350 mg twice daily |
Note: Based on a population pharmacokinetic analysis in 112 immunocompromised paediatric patients aged 2 to <12 years and 26 immunocompromised adolescents aged 12 to <17 years.
It is recommended to initiate the therapy with intravenous regimen, and oral regimen should be considered only after there is a significant clinical improvement. It should be noted that an 8 mg/kg intravenous dose will provide voriconazole exposure approximately 2-fold higher than a 9 mg/kg oral dose.
If patient response to treatment is inadequate, the intravenous dose may be increased by 1 mg/kg steps. If patient is unable to tolerate treatment, reduce the intravenous dose by 1 mg/kg steps.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
